Improved Antitumor Effects of Immunotoxins Prepared with Deglycosylated Ricin A-Chain and Hindered Disulfide Linkages

Cancer Research

Volumn 48, Issue 22, 1988, Pages 6396-6403

  Thorpe, Philip E ^a   Wallace, Philip M ^a   Knowles, Phillip P ^a   Relf, Michele G ^a   Brown, Alex N ^a   Watson, Graham J ^a   Blakey, David C ^a,b   Newell, David R ^c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; RICIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CONJUGATION; CROSS LINKING; DISULFIDE BOND; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG STABILITY; FEMALE; GLYCOSYLATION; IMMUNOTOXINS; ISOANTIBODIES; LETHAL DOSE 50; LYMPHOMA; MICE; MICE, INBRED AKR; MICE, INBRED BALB C; RICIN; TUMOR CELLS, CULTURED;

EID: 0023689869     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Blakey, D. C., Watson, G. J., Knowles, P. P., and Thorpe, P. E. Effect of chemical dcglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy-1.1 antibody. Cancer Res., 47: 947-952, 1987.
2. Raso, V., and Basala, M. Monoclonal antibodies as cell targeted carriers of covalently and non-covalently attached toxins. NATO Adv. Study Inst. Ser. A Life Sci., 82: 119-138. 1985.
3. Worrell. N. R., Cumber, A. J., Parnell, G. D., Ross, W. C. J., and Forrester, J. A. Fate of an antibody-ricin A chain conjugate administered to normal rats. Biochem. Pharmacol., 55: 417-423, 1986.
4. Skilleter. D. N., Price, R. J., and Thorpe, P. E. Modification of the carbo hydrate in ricin with metaperiodate and cyanoborohydride mixtures: effect on binding, uptake and toxicity to parenchymal and non-parenchymal cells of rat liver. Biochim. Biophys. Acta, 842: 12-21, 1985.
5. Blakey. D. C., and Thorpe, P. E. Effect of chemical deglycosylation on the in vivo fate of ricin A chain. Cancer Drug Delivery, 3: 189-195, 1986.
6. Bourrie, B. J. P., Casellas, P., Blythman, H. E., and Jansen. F. K. Study of the plasma clearance of antibody-ricin A-chain immunotoxins. Evidence for specific recognition sites that mediate rapid clearance of the immunotoxin. Eur. J. Biochem., 155: 1-10. 1986.
7. Skilleter, D. N., and Foxwell. B. M. J. Selective uptake of ricin A chain by hepatic non-parenchymal cells in vitro. Importance of mannose oligosaccha rides in the toxin. FEBS Lett., 196: 344-348, 1986.
8. Blakey, D. C., Skilleter, D. N., Price, R. J., and Thorpe, P. E. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver paren chymal and non-parenchymal cells in vitro and in vivo. Biochim. Biophys. Acta, 968: 172-178, 1988.
9. Thorpe, P. E., Detre, S. I., Foxwell, B. M. J., Brown, A. N. F., Skilleter, D. N., Wilson, G., Forrester, J. A., and Stirpe, F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur. J. Biochem., 147: 197-206, 1985.
10. Fulton. R. J., Tucker, T. F., Vitetta. E. S., and Uhr, J. W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the A chain on clearance and tumor localization. Cancer Res., 48: 2618-2625, 1988.
11. Fulton, R. J., Uhr, J. W., and Vitetta, E. S. In vivo therapy of the BCL, tumor: effect of immunotoxin valency and deglycosylation of ricin A chain. Cancer Res., 48: 2626-2631, 1988.
12. Thorpe, P. E., Blakey, D. C., Brown, A. N. F., Knowles. P. P., Knyba, R. E., Wallace, P. M., Watson, G. J., and Wawrzynczak, E. J. Comparison of two anti-Thy l.I-abrin A-chain immunotoxins prepared with different crosslinking agents: antitumor effects, in vivo fate, and tumor cell mutants. J. Natl. Cancer Inst., 79: 1101-1112, 1987.
13. Strand, M., Scheinberg, D. A., and Gansow, O. A. Monoclonal antibody conjugates for tumor imaging and therapy. In: R. F. Beers and E. G. Bassett (eds.). Cell Fusion: Gene Transfer and Transformation, pp. 385-393. New York: Raven Press, 1984.
14. Lelvin, N. L., Goldmacher, V. S., Rilz, J., Yetz, J. M., Schlossman, S. F., and Lambert, J. M. In vivoadministration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. J. Clin. Invest., 77: 977-984, 1986.
15. Scott, C. F., Goldmacher, V. S., Lambert. J. M., Jackson, J. V., and Mclntyre, G. D. An immunotoxin composed of a monoclonal antitransfemn receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. J. Natl. Cancer Inst., 79: 1163-1172, 1987.
16. Blakey, D. C., and Thorpe, P. E. An overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunoconj. Radiopharm., 1: 1-16, 1988.
17. Masuho, Y., Kishida, K., Saito, M., Umemoto, N., and Hara, T. Importance of the antigen-binding valency and the nature of the cross-linking bond inricin A-chain conjugates with antibody. J. Biochem. (Tokyo), 91: 1583-1591, 1982.
18. Thorpe, P. E., Wallace, P. M., Knowles, P. P., Reif, M. G., Brown, A. N. F., Watson, G. J., Knyba, R. E., Wawrzynczak, E. J., and Blakey, D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res., 47: 5924-5931, 1987.
19. Worrell, N. R., Cumber, A. J., Pamell, G. D., Mirza. A., Forrester, J. A., and Ross, W. C. J. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anticancer Drug Design, 1: 179-188, 1986.
20. Mason, D. W., and Williams, A. F. The kinetics of antibody binding to membrane antigens in solution and at the cell surface. Biochem. J., 187: 1-20, 1980.
21. Cumber, A. J., Forrester, J. A., Foxwell, B. M. J., Ross, W. C. J., and Thorpe, P. E. Preparation of antibody-toxin conjugates. Methods Enzymol., 112: 207-225, 1985.
22. Fulton, J. R., Blakey, D. C., Knowles, P. P., Uhr, J. W., Thorpe, P. E., and Vitella, E. S. Purification of ricin AI. A2 and B-chains and characterization of their toxicity. J. Biol. Chem., 261: 5314-5319, 1986.
23. Vitella, E. S., and Thorpe, P. E. Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro. Cancer Drug Delivery, 2: 191-198, 1985.
24. Knowles, P. P., and Thorpe, P. E. Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal. Biochem., 160: 440-443, 1987.
25. Thorpe, P. E., Brown, A. N. F., Ross, W. C. J., Cumber, A. J., Detre, S. I., Edwards. D. C., Davies, A. J. S., and Stirpe, F. Cytotoxicity acquired by conjugation of an anti-Thy I.I monoclonal antibody and the ribosomeinactivating protein, gelonin. Eur. J. Biochem., 116: 447-454. 1981.
26. Wish, L., Furth, J., and Storey, R. H. Direct determinations of plasma, cell, and organ-blood volumes in normal and hypervolemic mice. Proc. Soc. Exp. Biol. Med., 74: 644-649, 1950.
27. Jennrich, R. I., and Sampson, P. F. Application of stepwise regression to non-linear least squares estimation. Technometrics. 10: 63-72, 1968.
28. Ottaway. J. H. Normalization in the fitting of data by iterative methods. Biochem. J., 134: 729-737, 1973.
29. Wagner, J. G. In: Fundamentals of Clinical Pharmacokinetics, p. 82. Washington, DC: Drug Intelligence Publications, 1975.
30. Houston, J. B. Kinetics of drug metabolism and disposition: physiological determinants. In: G. R. Wilkinson and M. D. Rawlins (eds.). Drug Metabolism and Disposition: Considerations in Clinical Pharmacology, pp. 63-90. Lancaster, England: MTP Press, 1985.
31. Anderson, M. E., and Meister, A. Dynamic state of glutathione in blood plasma. J. Biol. Chem., 255: 9530-9533, 1980.
32. Breslow, N. A generalized Kruskal Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika. 57: 579-594, 1970.
33. Weil, C. Tables for convenient calculation of median-effective dose (LD50 or ED50)and instructions in their use. Biometrics, 8: 249-252, 1952.
34. Jansen, F. K., Blythman, H. E., Bourrie, B., Carriere, D., Casellas, P., Dussossoy, D., Gros, O., Laurent, J. C., Liance, M. C., Poncelet, P., Richer, G., and Vidal, H. Significance of the kinetics of immunotoxin cytotoxicity. Adv. Study Inst. Ser. A Life Sci., 82: 147-178. 1985.
35. Thorpe, P. E., Brown, A. N. F., Bremner. J. A. G., Foxwell, B. M. J., and Stirpe. F. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J. Natl. Cancer Inst., 75: 151-159. 1985.
36. Jansen, F. K., Blythman, H. E., Carriere. D., Casellas, P., Gros, O., Gros, P., Laurent, J. C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal. H., and Voisin, G. A. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol. Rev., 62: 185-216, 1982.
37. Krolick, K. A., Uhr. J. W., Slavin, S., and Vitella, E. S. In vivo therapy of a murine B-cell tumor (BCL) using antibody-ricin A chain immunotoxins. J. Exp. Med., 755: 1797-1809, 1982.
38. Seto, M., Umemoto, N., Saito, M., Masuho, Y., Hara, T., and Takahashi, T. Monoclonal anti-MM46 antibody-ricin A chain conjugate. In vitro and in vivo antitumor activity. Cancer Res., 42: 5209-5215, 1982.
39. Hara, H., and Seon, B. K. Complete suppression of in vivogrowth of human leukemia cells by specific immunotoxins: nude mouse models. Proc. Natl. Acad. Sci. USA, 84: 3390-3394, 1987.
40. Sivam, G., Pearson, J. W., Bohn, W., Oldham. R. K., Sadoff, J. C., and Morgan, A. C. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A-chain conjugates. Cancer Res., 47: 3169-3173, 1987.
41. Byers, V. S., Pimm, M. V., Scannen. P. J., Pawluczyk, I., and Baldwin, R. W. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791 T/36 conjugates. Cancer Res., 47: 5042-5046. 1987.
42. Ramakrishnan. S., and Houston. L. L. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosome inhibitors: pokeweed antiviral protein or ricin A chain. Cancer Res., 44: 1398-1404. 1984.
43. Hwang, K. M., Foon. K. A., Cheung, P. H., Pearson, J. W., and Oldham. R. K. Selective antitumor effect on LIO hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res., 44: 4578-4586, 1984.
44. FitzGerald. D. J., Bjorn.M. J., Ferris. R. J., Winkelhake, J. L., Frankel, A. E., Hamilton, T. C., Ozols, R. F., Willingham. M. C., and Pastan. I. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. Cancer Res., 47: 1407-1410, 1987.
45. Scott, C. F., Goldmacher, V. S., Lambert, J. M., Chari, R. V. J., Bolender, S., Gauthier, M. N., and Blattler, W. A. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy 1 antibody disulfide linked to the ribosome-inactivating protein gelonin. Cancer Immunol. Immunother., 25: 31-40, 1987.
46. Glennie, M. J., McBride. H. M., Stirpe, F., Thorpe, P. E., Worth, A. T., and Stevenson, G. T. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin. J. Exp. Med., 766: 43-62, 1987.
47. Hyman, R., and Trowbridge, I. Analysis of the biosynthesis of T25 (Thy-1) in mutant lymphoma cells: a model for plasma membrane glycoprotein synthesis. Cold Spring Harbor Conf. Cell Proliferation. 5: 741-754, 1978.
48. Goldmacher, V. S., Anderson, J., Schulz, M., Blattler, W. A., and Lambert, J. M. Somatic cell mutants resistant to ricin, diphtheria toxin and to immunotoxins. J. Biol. Chem., 262: 3205-3209, 1987.